The gut-renal axis: do incretin-based agents confer renoprotection in diabetes?
about
The treatment of type 2 diabetes in the presence of renal impairment: what we should know about newer therapiesRecent advances in managing and understanding diabetic nephropathyNephroprotection by Hypoglycemic Agents: Do We Have Supporting Data?Targeting gut microbiota: a potential promising therapy for diabetic kidney diseaseStereomicroscopic 3D-pattern profiling of murine and human intestinal inflammation reveals unique structural phenotypesThe regulatory role of DPP4 in atherosclerotic disease.Sitagliptin ameliorates oxidative stress in experimental diabetic nephropathy by diminishing the miR-200a/Keap-1/Nrf2 antioxidant pathway.Treatment of diabetic kidney disease: current and future targets.Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.Cardiovascular, renal and gastrointestinal effects of incretin-based therapies: an acute and 12-week randomised, double-blind, placebo-controlled, mechanistic intervention trial in type 2 diabetes.GLP-1 receptor agonists: Nonglycemic clinical effects in weight loss and beyond.Gastrorenal communication: sniffing and tasting.Acute renal effects of the GLP-1 receptor agonist exenatide in overweight type 2 diabetes patients: a randomised, double-blind, placebo-controlled trialRenoprotective Effect of Gemigliptin, a Dipeptidyl Peptidase-4 Inhibitor, in Streptozotocin-Induced Type 1 Diabetic Mice.Dipeptidyl peptidase-4 inhibition by Saxagliptin prevents inflammation and renal injury by targeting the Nlrp3/ASC inflammasome.Associations of dipeptidyl peptidase-4 inhibitors with mortality in hospitalized heart failure patients with diabetes mellitus.New therapeutic agents in diabetic nephropathy.Extra-pancreatic effects of incretin-based therapies.Therapeutic approaches to diabetic nephropathy--beyond the RAS.A review of gliptins for 2014.Diabetic nephropathy: landmark clinical trials and tribulations.Postprandial renal haemodynamic effect of lixisenatide vs once-daily insulin-glulisine in patients with type 2 diabetes on insulin-glargine: An 8-week, randomised, open-label trial.The Place of Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Therapeutics: A "Me Too" or "the Special One" Antidiabetic Class?GLP-1 Agonists and Blood Pressure: A Review of the Evidence.Lipotoxicity as a trigger factor of renal disease.The incretin system ABCs in obesity and diabetes - novel therapeutic strategies for weight loss and beyond.Anti-inflammatory role of DPP-4 inhibitors in a nondiabetic model of glomerular injury.Diabetes, hypertension, and chronic kidney disease progression: role of DPP4.Glomerular Hyperfiltration in Diabetes: Mechanisms, Clinical Significance, and Treatment.Exenatide acutely increases heart rate in parallel with augmented sympathetic nervous system activation in healthy overweight males.Renal Effects of SGLT-2 Inhibitors and Other Anti-diabetic Drugs: Clinical Relevance and Potential Risks.Evaluation of Serum Spondin 2 Levels in the Different Stages of Type 2 Diabetic Nephropathy.Enteric dysbiosis-linked gut barrier disruption triggers early renal injury induced by chronic high salt feeding in mice.Renoprotective Effects of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin: A Review in Type 2 Diabetes.Saxagliptin Attenuates Albuminuria by Inhibiting Podocyte Epithelial- to-Mesenchymal Transition via SDF-1α in Diabetic Nephropathy.Treatment effects of renin-angiotensin aldosterone system blockade on kidney failure and mortality in chronic kidney disease patients.Michaela Diamant, 11 April 1962-9 April 2014.Role of the sodium-hydrogen exchanger in mediating the renal effects of drugs commonly used in the treatment of type 2 diabetes.CAPE-pNO2 ameliorated diabetic nephropathy through regulating the Akt/NF-κB/ iNOS pathway in STZ-induced diabetic mice.The renoprotective effect and safety of a DPP-4 inhibitor, sitagliptin, at a small dose in type 2 diabetic patients with a renal dysfunction when changed from other DPP-4 inhibitors: REAL trial.
P2860
Q26744317-E097D86D-8026-4B0A-8075-B1FF0DB96002Q26745900-82972030-3C2F-42B5-A4D0-E2DCF0548A25Q26777994-6B00C9D5-B7D7-42F6-86C0-E29BC828B556Q28078235-76FC6A54-9685-409B-B398-508C0633E8A3Q30658529-36E7A686-3CD6-44F6-9D5D-2AB0E4AEA934Q33805518-06745B70-0F34-4E98-B5D0-02765DEE8A39Q33806760-DB9D9A11-4579-493E-B8F1-71ABC03F64FCQ33907249-9087A24D-3C25-4475-91B7-7E3780D07602Q36050559-29752BE2-018C-4358-9DB8-E6AB83010082Q36302662-B899D1AC-13D3-471A-A65F-F1A23ED820B1Q36406821-254D89D3-829A-493D-BAFF-1E30710A9E91Q36760763-927BD175-774B-4BB0-BD36-12A78799122FQ36990093-65AFC270-A95B-4D78-85B9-4F24ABC7A420Q37056839-ECA87C57-8549-4925-A444-2618749555E9Q37177528-CB282D01-8C01-448E-BBF0-68C830A24F93Q37337371-BF7430D7-C2EC-464D-A09D-0BA779EB6BF7Q37559164-F2BBD75C-25CE-446C-9CFA-C82AE5333A29Q38194069-41BBB317-A69F-4ACB-AA00-9621BD86F400Q38209811-A5249AAF-A904-4C46-ACD7-6E9A10DEEAF4Q38266290-4CE57ABA-45AD-4A74-94E3-5246719E5590Q38338539-DD3D1DE8-73E2-446D-AF21-87D320D40CFFQ38377453-4847A172-AE75-4B44-A9BA-574318F2D58AQ38527885-03EB17B9-B64C-42A7-9CEF-AC4EF1BD809CQ38709406-086E1BA7-BEB3-4723-B962-9CBE496F3900Q38765934-EE8DF287-D37B-4426-A980-962679040D6BQ38820260-2791C104-4E81-4F41-A573-A28D1DAE6717Q38912532-07D04B92-F8B7-4A7C-9884-65D923EA4190Q39103371-95B7623B-39BF-43FD-894E-274BF1820E26Q39112475-D8E40F35-6531-4493-AC6C-267921912A44Q39220482-C2F943B2-784F-4548-98AF-4B7F69B1D91EQ39290337-6993D53B-3C4C-451F-9B07-DBC257809CF8Q40940267-4ECDD478-856B-4E3D-8312-D47BEEF7FFE2Q41583258-CA3861D9-7F72-4B89-BDE9-450C7EBFA740Q42876331-8BF76065-EBC5-4856-8F65-C1A2402CF521Q47099497-AB87D95D-9CA5-4B24-9285-2EB3A13C882DQ47153972-E34078F6-DEB2-4D75-A19B-4DC8517AE7EFQ48077455-3B517EB8-46A9-4484-8308-26963005A756Q48141985-475AB40A-4AF1-4EF3-950F-1AAA078DFCD1Q49226476-64F38D91-AABC-46E4-8CA0-1EC991BEBB04Q49592715-CA2E7259-7B08-4694-B91C-F74DF531BD96
P2860
The gut-renal axis: do incretin-based agents confer renoprotection in diabetes?
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
The gut-renal axis: do incretin-based agents confer renoprotection in diabetes?
@en
type
label
The gut-renal axis: do incretin-based agents confer renoprotection in diabetes?
@en
prefLabel
The gut-renal axis: do incretin-based agents confer renoprotection in diabetes?
@en
P2860
P50
P356
P1476
The gut-renal axis: do incretin-based agents confer renoprotection in diabetes?
@en
P2093
Michaela Diamant
P2860
P2888
P304
P356
10.1038/NRNEPH.2013.272
P407
P577
2013-12-24T00:00:00Z